Analysts expect Amphastar Pharmaceuticals Inc (NASDAQ:AMPH) to post sales of $62.58 million for the current quarter, according to Zacks Investment Research. Three analysts have issued estimates for Amphastar Pharmaceuticals’ earnings. The lowest sales estimate is $56.70 million and the highest is $67.73 million. Amphastar Pharmaceuticals reported sales of $63.54 million during the same quarter last year, which would suggest a negative year over year growth rate of 1.5%. The business is scheduled to issue its next earnings report on Monday, March 12th.
According to Zacks, analysts expect that Amphastar Pharmaceuticals will report full year sales of $62.58 million for the current year, with estimates ranging from $234.00 million to $247.51 million. For the next year, analysts anticipate that the business will report sales of $312.39 million per share, with estimates ranging from $299.80 million to $325.30 million. Zacks Investment Research’s sales averages are a mean average based on a survey of research firms that follow Amphastar Pharmaceuticals.
Amphastar Pharmaceuticals (NASDAQ:AMPH) last released its quarterly earnings results on Wednesday, November 8th. The company reported $0.07 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.02 by $0.05. The firm had revenue of $57.90 million for the quarter, compared to the consensus estimate of $57.23 million. Amphastar Pharmaceuticals had a return on equity of 2.30% and a net margin of 0.12%. The firm’s quarterly revenue was down 9.8% compared to the same quarter last year. During the same quarter last year, the business posted $0.14 EPS.
Shares of Amphastar Pharmaceuticals (AMPH) opened at $19.37 on Monday. Amphastar Pharmaceuticals has a 1 year low of $12.05 and a 1 year high of $19.95. The company has a debt-to-equity ratio of 0.13, a quick ratio of 1.86 and a current ratio of 3.08. The firm has a market capitalization of $890.55, a P/E ratio of 129.13, a price-to-earnings-growth ratio of 1.36 and a beta of 1.69.
In other news, Director Stephen B. Shohet sold 7,866 shares of the firm’s stock in a transaction that occurred on Thursday, December 14th. The stock was sold at an average price of $18.87, for a total value of $148,431.42. Following the completion of the sale, the director now directly owns 31,982 shares of the company’s stock, valued at approximately $603,500.34. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Stephen B. Shohet sold 7,862 shares of the firm’s stock in a transaction that occurred on Thursday, November 2nd. The shares were sold at an average price of $18.37, for a total value of $144,424.94. The disclosure for this sale can be found here. Insiders have sold a total of 72,787 shares of company stock valued at $1,359,684 over the last ninety days. 11.10% of the stock is owned by insiders.
Several institutional investors and hedge funds have recently bought and sold shares of the company. Vanguard Group Inc. lifted its holdings in shares of Amphastar Pharmaceuticals by 10.8% in the 2nd quarter. Vanguard Group Inc. now owns 2,414,797 shares of the company’s stock valued at $43,128,000 after buying an additional 235,033 shares during the period. Dimensional Fund Advisors LP lifted its holdings in shares of Amphastar Pharmaceuticals by 17.0% in the 3rd quarter. Dimensional Fund Advisors LP now owns 1,558,113 shares of the company’s stock valued at $27,844,000 after buying an additional 226,271 shares during the period. Teachers Advisors LLC lifted its holdings in shares of Amphastar Pharmaceuticals by 1.1% in the 2nd quarter. Teachers Advisors LLC now owns 549,149 shares of the company’s stock valued at $9,808,000 after buying an additional 6,196 shares during the period. Northern Trust Corp lifted its holdings in shares of Amphastar Pharmaceuticals by 2.0% in the 2nd quarter. Northern Trust Corp now owns 485,706 shares of the company’s stock valued at $8,675,000 after buying an additional 9,672 shares during the period. Finally, UBS Asset Management Americas Inc. lifted its holdings in shares of Amphastar Pharmaceuticals by 143.0% in the 2nd quarter. UBS Asset Management Americas Inc. now owns 362,947 shares of the company’s stock valued at $6,482,000 after buying an additional 213,572 shares during the period. 44.00% of the stock is owned by institutional investors and hedge funds.
WARNING: This article was originally reported by American Banking News and is owned by of American Banking News. If you are accessing this article on another publication, it was illegally copied and republished in violation of US & international copyright & trademark law. The original version of this article can be viewed at https://www.americanbankingnews.com/2018/01/22/zacks-analysts-anticipate-amphastar-pharmaceuticals-inc-amph-will-post-quarterly-sales-of-62-58-million.html.
About Amphastar Pharmaceuticals
Amphastar Pharmaceuticals, Inc is a specialty pharmaceutical company. The Company focuses primarily on developing, manufacturing, marketing and selling generic and injectable, inhalation and intranasal products. The Company has two segments: finished pharmaceutical products and active pharmaceutical ingredients (API) products.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Amphastar Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amphastar Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.